Navigation Links
CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum
Date:10/19/2011

BUFFALO, N.Y., Oct. 19, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, announced today that H. Shep Wild, President and Chief Executive Officer, will present a company overview at the Biotechnology Industry Organization's 10th Annual BIO Investor Forum in San Francisco, CA on Wednesday, October 26 at 9:00 am.

The BIO Investor Forum features presentations by leading private and emerging public biotechnology companies to healthcare venture and private equity investors, buy-side and sell-side investment companies and biopharmaceutical and industry business development and licensing executives.

CureFAKtor's proprietary FAK technology platform may represent a significant breakthrough in the treatment of most solid tumors in that its unique mechanism of action disrupts the signaling of FAK in tumors by targeting specific protein to protein bindings.  CureFAKtor scientists first discovered FAK in human tumors approximately 20 years ago.  FAK is much like a force field that cocoons cancer cells and allows them to survive the effects of chemotherapy, radiation and other natural processes designed to execute aberrant cancer cells.  Since FAK is over-expressed in virtually all solid tumors, the technology has broad applicability in oncology.

More than 40 compounds have been identified that target FAK signaling sites.  In preclinical studies, lead small molecule oral compound CFAK-C4 demonstrated efficacy in a number of cancers including pancreatic, breast, advanced melanoma and neuroblastoma. The Company's second product candidate, CFAK-Y15 is being investigated for the treatment of breast, pancreatic, neuroblastoma and colon cancer. The Company has promising results with CFAK-Y15 in lung cancer and glioblastoma.

CureFAKtor received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for CFAK-C4 in combination with gemcitabine for the treatment of pancreatic cancer, a disease with the lowest survival rate of any cancer and limited patient treatment options, and is planning a Phase I clinical study in 2012.

Additional information about the company may be found at www.curefaktor.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for CureFAKtor Pharmaceuticals that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. 

Media Contact
Rx Communications Group, LLC
Eric Goldman
Vice President, Public Relations
917-322-2563
egoldman@rxir.com


'/>"/>
SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
2. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
3. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... December 5, 2016 BioLineRx Ltd. (NASDAQ/TASE: ... developing promising therapeutic candidates, presents positive Phase 2a correlative data, ... leading oncology platform at the ongoing 58th American Society of ... Diego, California . ... , , As ...
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 ... alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response ... and tolerability profile of ropeginterferon alfa-2b versus HU ... ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing authorization ... present this data to the FDA as it seeks approval ...
(Date:12/4/2016)... 3, 2016   Pairnomix, LLC, a genetic research ... recognized by the White House, today announced that findings from ... identification of candidate therapies for a patient with epileptic encephalopathy ... were presented at the 70 th Annual Meeting of ... TX , December 2-6, 2016.  Pairnomix, unique ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... Sideline Products is a Southern York County ... the smaller rider and the horse. Smaller saddles can pinch and irritate the horse ... fit over a properly fitted western saddle so it does not impact the comfort ...
(Date:12/5/2016)... ... ... “Life Will Never Be The Same” is a fictional tale about growing up with ... is the creation of published author, Kim T. Briggs, a self-described “big kid” who ... religion and philosophy from Judson University in Elgin, Illinois. Having written numerous Christian drama ...
(Date:12/5/2016)... ... , ... Sabah Shah MD, MBA has joined the Retina Group of New York ... by James M. Maisel, MD and has been providing tertiary medical and surgical retinal care ... of surpassing expectations amongst her peers. Growing up in a family of doctors, Dr. ...
(Date:12/5/2016)... Greifensee, Switzerland (PRWEB) , ... ... ... testing between professional calibrations is an excellent way to ensure moisture measurements ... methods are time-consuming and impractical. , Now, METTLER TOLEDO offers a ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... CardioQuick Patch® significantly improves the reproducibility and accuracy of placing precordial electrodes with ... , Over the last 60 years, studies have shown that single electrode ...
Breaking Medicine News(10 mins):